Seizing the evidence that PPARβ/δ agonist alleviated the diabetic osteoporosis phenotypes and reduced osteoclast activity in vivo, we speculated that PPARβ/δ might directly inhibit osteoclast differentiation. Here, PPARD is linked to osteoporosis.